Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 15 of 15 publications.

Mohamed AF, Johnson FR, Epstein JD, Li-McLeod JM. Failure to communicate? Subjective and objective risks from a hemophilia: a treatment preference study.. Presented at the Third Conjoint Analysis in Health Conference; October 2010.

Lynen R, Taylor TN, Farkouh RA, Candrilli SD, Graham J, Colligs A. The effect of age, race, and folic acid-containing supplements on red blood cell folate levels among United States women of child bearing age. Poster presented at the ASRM Annual Meeting; October 26, 2010. [abstract] Fertil Steril. 2010 Sep; 94(4, Suppl 1):S93. doi: 10.1016/j.fertnstert.2010.07.392

Knight C, Plun-Favreau J, Johal S. An economic model to evaluate the cost-effectiveness of prophylaxis regimens on haemophilia patients with inhibitors. Poster presented at the XXIXth International Congress of the World Federation of Hemophilia; July 2010. Buenos Aires, Argentina. [abstract] Haemophilia. 2010 Jun; 16(Suppl 4):127.

Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, Fryzek J, Kaye JA. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010 Jun 1;149(6):855-64.

Jick SS, Hagsberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception. 2010 May;81(5):452-3.

Roskell N, Wolowacz S, Christiansen AV, Plumb JM. Are double-blind, double-dummy studies suitable for resource utilisation analyses? An example from a new oral anticoagulant for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A167.

Reese ES, Mullins CD, Beitelshees AL, Onukwugha E. The cost-effectiveness of genotyping CYP 2C19 to guide antiplatelet therapy selection. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. Previously presented at the University of Maryland Graduate Research Conference.

Reese ES, Mullins CD, Beitelshees AL, Onukwugha E. The cost-effectiveness of genotyping CYP 2C19 to guide antiplatelet therapy selection. Presented at the University of Maryland Graduate Research Conference; April 2010.

Ritchey ME, Jonsson Funk ML, Marshall SW, Marinac-Dabic D, Rutala WA, Weber DJ. Changing rate of bloodstream infection across duration of central venous access. Poster presented at the 5th Decennial International Conference on Healthcare-Associated Infections; March 20, 2010. Atlanta, GA. Previously presented at the 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

Stull DE, Vernon MK, Legg JC, Viswanathan HN, Fairclough D, Revicki DA. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue. Contemp Clin Trials. 2010 Mar;31(2):172-9. doi: 10.1016/j.cct.2009.12.006

Hauber AB, Johnson FR, Grotzinger KM, Ozdemir S. Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies. Ann Pharmacother. 2010 Mar 1;44(3):479-88.

Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ. Economic evaluation of dabigatran etexilate for the preventionof venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement. Thromb Haemost. 2010 Feb 1;103(2):360-71.

Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA® and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception. 2010 Jan 1;81(1):16-21.

Zaniolo O, Wolowacz SE, Pradelli L. Economic performance of dabigatran etexilate for primary VTE prevention following total hip and knee replacement surgery in Italy [Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia]. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.

Zaniolo O, Wolowacz SE, Pradelli L. Modello di costo/efficacia di dabigatran nella profilassi del tromboembolismo venoso in chirurgia ortopedica maggiore: adattamento per l'Italia. Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2010;11(2):91-101.